Literature DB >> 16753226

Effects of interferon-beta on oligodendroglial cells.

Sandra Heine1, Jens Ebnet, Samaneh Maysami, Martin Stangel.   

Abstract

The effect of interferon-beta (IFN-beta) for the treatment of multiple sclerosis (MS) is thought to be mediated by the modulation of immune cells. In addition, it has been shown that glial cells may be influenced by IFN-beta and a role during remyelination has been suggested. However, the mechanism is not yet clear and there are conflicting data. We have therefore systematically investigated proliferation, differentiation, toxicity, and cytoprotection of IFN-beta on oligodendroglia, both as a direct effect and mediated indirectly via other glial cells. Differentiation of oligodendrocyte progenitor cells (OPC) was significantly (p<0.01) inhibited by IFN-beta only when cultured in the presence with astrocytes and microglia. Proliferation was not changed, neither was IFN-beta toxic. There was no cytoprotective effect of IFN-beta on oligodendroglia injury induced by H2O2, NO, complement, or glutamate. Similarly, there was no cytoprotective effect mediated via treatment of astrocytes with IFN-beta. These data demonstrate that IFN-beta is neither toxic nor cytoprotective for oligodendrocytes. In summary, the only effect of IFN-beta was the inhibition of differentiation of OPC mediated indirectly via other glial cells. In vivo experiments will show how this effect may influence remyelination.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16753226     DOI: 10.1016/j.jneuroim.2006.04.016

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  11 in total

1.  Type I IFN signaling in T regulatory cells modulates chemokine production and myeloid derived suppressor cells trafficking during EAE.

Authors:  Shalini Tanwar; Cihan Oguz; Amina Metidji; Eric Dahlstrom; Kent Barbian; Kishore Kanakabandi; Lydia Sykora; Ethan M Shevach
Journal:  J Autoimmun       Date:  2020-07-22       Impact factor: 7.094

2.  Overexpression of the dominant-negative form of interferon regulatory factor 1 in oligodendrocytes protects against experimental autoimmune encephalomyelitis.

Authors:  Zhihua Ren; Yan Wang; Duan Tao; David Liebenson; Thomas Liggett; Rajendra Goswami; Robert Clarke; Dusan Stefoski; Roumen Balabanov
Journal:  J Neurosci       Date:  2011-06-08       Impact factor: 6.167

3.  Human Schwann cells retain essential phenotype characteristics after immortalization.

Authors:  Helmar C Lehmann; Weiran Chen; Ruifa Mi; Shuo Wang; Ying Liu; Mahendra Rao; Ahmet Höke
Journal:  Stem Cells Dev       Date:  2011-07-06       Impact factor: 3.272

Review 4.  Role of cytokines as mediators and regulators of microglial activity in inflammatory demyelination of the CNS.

Authors:  Tobias D Merson; Michele D Binder; Trevor J Kilpatrick
Journal:  Neuromolecular Med       Date:  2010-03-30       Impact factor: 3.843

5.  Cooperative contributions of interferon regulatory factor 1 (IRF1) and IRF8 to interferon-γ-mediated cytotoxic effects on oligodendroglial progenitor cells.

Authors:  Makoto Horiuchi; Aki Itoh; David Pleasure; Keiko Ozato; Takayuki Itoh
Journal:  J Neuroinflammation       Date:  2011-01-24       Impact factor: 8.322

Review 6.  Cytokines and myelination in the central nervous system.

Authors:  Thomas Schmitz; Li-Jin Chew
Journal:  ScientificWorldJournal       Date:  2008-11-02

Review 7.  Therapeutic Potential of Cytokines in Demyelinating Lesions After Stroke.

Authors:  Yi-Sha Guo; Mei Yuan; Yu Han; Xin-Ya Shen; Zhen-Kun Gao; Xia Bi
Journal:  J Mol Neurosci       Date:  2021-05-10       Impact factor: 3.444

8.  Effects of fumaric acids on cuprizone induced central nervous system de- and remyelination in the mouse.

Authors:  Darius Moharregh-Khiabani; Alexander Blank; Thomas Skripuletz; Elvira Miller; Alexandra Kotsiari; Viktoria Gudi; Martin Stangel
Journal:  PLoS One       Date:  2010-07-23       Impact factor: 3.240

9.  A beta-lactam antibiotic dampens excitotoxic inflammatory CNS damage in a mouse model of multiple sclerosis.

Authors:  Nico Melzer; Sven G Meuth; Delany Torres-Salazar; Stefan Bittner; Alla L Zozulya; Christian Weidenfeller; Alexandra Kotsiari; Martin Stangel; Christoph Fahlke; Heinz Wiendl
Journal:  PLoS One       Date:  2008-09-05       Impact factor: 3.240

Review 10.  Molecular Effects of FDA-Approved Multiple Sclerosis Drugs on Glial Cells and Neurons of the Central Nervous System.

Authors:  Kim M A De Kleijn; Gerard J M Martens
Journal:  Int J Mol Sci       Date:  2020-06-13       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.